Monthly Archives: February 2017

INVESTOR ALERT: Levi & Korsinsky, LLP Has Filed a Complaint to Recover Losses Suffered by Investors in Northern Dynasty Minerals Ltd. Lead Plaintiff Deadline of April 17, 2017 – NAK

NEW YORK, NY / ACCESSWIRE / February 27, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Northern Dynasty Minerals Ltd. (“Northern Dynasty”) (NYSE MKT: NAK) between September 16, 2013 and February 14, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Kirwin v. Northern Dynasty Minerals Ltd., et al. (Case No. 1:17-cv-01238) in the United States District Court for the Southern District of New York. Click here to view the complaint. To get more information, go
to: http://www.zlk.com/pslra-sa/northern-dynasty-minerals-ltd, or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) The Pebble Project carries a negative net present value; (ii) the Pebble Project is not commercially viable; and (iii) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Northern Dynasty’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On February 14, 2017, shares of Northern Dynasty stock plummeted during intraday trading following the publication of a report on Seeking Alpha alleging that “Northern Dynasty is worthless” because its Pebble Project is not “commercially viable.”

If you suffered a loss in Northern Dynasty, you have until April 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 456068

INVESTOR ALERT: Levi & Korsinsky, LLP Has Filed a Complaint to Recover Losses Suffered by Investors in Sito Mobile, Ltd. Lead Plaintiff Deadline of April 18, 2017 – SITO

NEW YORK, NY / ACCESSWIRE / February 27, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired common stock of Sito Mobile, Ltd. (“Sito”) (NASDAQ CM: SITO) between February 9, 2016, and January 2, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Roper v. Sito Mobile Ltd., et al. (Case No. 2:17-cv-01106) in the United States District Court for the District of New Jersey. Click here to view the complaint. To get more information, go to: http://www.zlk.com/pslra/sito-mobile-ltd, or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Sito’s growth of bookings would not propel the Company’s fourth fiscal quarter 2016 media placement revenues and revenue growth to the level represented during the Class Period; (ii) Sito was aware that the election would impact the Company’s fourth fiscal quarter 2016 revenue, (iii) clients’ campaign spending and media placement revenues in the fourth quarter 2016 was highly dependent on the elections; (iv) the Company’s growth in media placement revenues would not occur in the fourth fiscal quarter 2016; (iv) as a result of the foregoing, the Company’s statements, as well as Defendants’ statements about Sito’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Sito, you have until April 18, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 456067

Trintech Releases Enhanced Reconciliation Solution

2Leading Global Provider of Financial Automation Focuses on Continuous Innovation by Investing in its Portfolio of Solutions with the Launch of T-Recs 7.2

DALLAS, TX / ACCESSWIRE / February 27, 2017 / Trintech, a leading global provider of automated Record to Report software solutions for the office of finance, today announced the release of T-Recs® 7.2, the latest version of its enterprise-class reconciliation solution. As reconciliation volumes and the variety of reconciliation types continue to increase, there is a need for enhanced process automation and extensive reconciliation processing power. T-Recs 7.2 is designed to support the needs of Trintech’s highest volume customers, many of which process tens of millions of transactions per day.

“With the release of T-Recs 7.2, we are excited to provide enhanced reconciliation capabilities to support the increasing demands financial professionals are facing,” said Michael Ross, Executive Vice President of Product Management at Trintech. “As we continue to innovate and invest in our portfolio of solutions, we are confident our customers will realize numerous benefits, including a reduction in manual work, improvement of process efficiencies, and overall lower costs across their finance organization.”

T-Recs 7.2 transforms the reconciliation process, delivering the advanced functionality and processing power required to automate General Ledger (GL) account reconciliations. Whether you are performing traditional reconciliations or advanced functions, such as identifying business risks, measuring ongoing performance, or assessing the effectiveness of internal controls over the entire GL, T-Recs reduces reconciliation hours and eliminates the errors and risk of manual operations.

If you would like more information on T-Recs 7.2, please contact us at moreinfo@trintech.com.

About Trintech

Trintech, Inc. pioneered the development of Financial Corporate Performance Management (FCPM) software to optimize the Record to Report process. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, managing intercompany workflow and transactions, journal entries, disclosure and fiduciary reporting and bank fee analysis, to governance, risk and compliance – Trintech’s portfolio of financial solutions, including Cadency®, ReconNETTM and T-Recs®, help manage all aspects of the financial close process. Over 1,700 clients worldwide – including the majority of the FTSE® 100 – rely on our cloud-based software to increase efficiency, reduce costs, and improve governance and transparency across global financial organizations.

Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, France, Ireland, the Netherlands, and the Nordics, as well as strategic partners in South Africa, Latin America, and Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook, and Twitter.

SOURCE: Trintech, Inc.

ReleaseID: 456044

Important Deadline Reminder for General Cable Corp. Shareholders

RADNOR, PA / ACCESSWIRE / February 27, 2017 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds General Cable Corporation (NYSE: BGC) (“General Cable” or the “Company”) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Company’s securities between February 23, 2012 and February 10, 2016, inclusive (the “Class Period”).

Important Deadline Reminder: General Cable shareholders who purchased their securities during the Class Period may, no later than March 6, 2017, seek to be appointed as a lead plaintiff representative of the class. For additional information, or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/general-cable-corporation#join.

General Cable Corporation designs, develops, manufactures, markets, and distributes copper, aluminum, and fiber optic wire and cable products for the energy, industrial, construction, and specialty and communications markets worldwide.

The Complaint alleges that during the Class Period General Cable and certain of its executive officers made false and/or misleading statements and/or failed to disclose that: (i) General Cable paid millions of dollars in bribes to government officials in foreign countries, including Angola, Bangladesh, China, Egypt, Indonesia, India, and Thailand, in order to secure business; (ii) the foregoing conduct was in violation of the Foreign Corrupt Practices Act (the “FCPA”); (iii) General Cable’s revenues were therefore in part the product of illegal conduct, and, as such, subject to disgorgement and unlikely to be sustainable; and (iv) the foregoing conduct, when it became known, would subject the Company to significant regulatory scrutiny and financial penalties. The complaint further alleges that, as a result of the foregoing, General Cable’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.

On September 22, 2014, General Cable disclosed that it was reviewing “payment practices,” “the use of agents,” and “the manner in which the payments were reflected on our books and records” in connection with the Company’s operations in Portugal, Angola, Thailand, and India. On this news, shares of the Company’s stock fell $0.93 per share, or 4.7%, to close at $18.96 on September 22, 2014.

Subsequently, on February 10, 2016, General Cable reported that it had increased a disgorgement accrual for a potential FCPA settlement to $33 million after identifying “certain other transactions that may raise concerns.” On this news, shares of the Company’s stock fell an additional $3.05 per share, or 31.6%, to close at $6.60 on February 11, 2016.

Finally, on December 29, 2016, The Wall Street Journal reported that General Cable had entered into a non-prosecution agreement with the U.S. Department of Justice and “agreed to pay $75.8 million to settle allegations it paid bribes across Africa and Asia and . . . agreed to an additional $6.5 million penalty to settle accounting-related violations.” The article further reported that the Company’s subsidiaries, “over a period of a dozen years, paid about $13 million to third-party agents and distributors,” who in turn “paid bribes to government officials in Angola, Bangladesh, China, Indonesia and Thailand to get business in violation of the Foreign Corrupt Practices Act.”

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299-7706 or (610) 667-7706, or via e-mail at info@ktmc.com.

General Cable shareholders may, no later than March 6, 2017, petition the Court to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. For additional information, or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/general-cable-corporation#join.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, or for additional information about participating in this action, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP

Darren J. Check, Esq.

D. Seamus Kaskela, Esq.

Adrienne O. Bell, Esq.

280 King of Prussia Road

Radnor, PA 19087

(888) 299-7706

(610) 667-7706

info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 452298

Kessler Topaz Meltzer & Check, LLP Reminds DaVita Inc. Shareholders of Important Deadline in Class Action Lawsuit

RADNOR, PA / ACCESSWIRE / February 27, 2017 / The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against DaVita Inc. (NYSE: DVA) (“DaVita” or the “Company”) on behalf of purchasers of the Company’s securities between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”).

Deadline Reminder: Investors who purchased DaVita securities during the Class Period may, no later than April 3, 2017, petition the Court to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/davita-inc#join.

DaVita provides kidney dialysis services for patients suffering from chronic kidney failure or end-stage renal disease. At relevant times, DaVita made contributions to the American Kidney Fund (“AKF”), a purported charitable foundation that provides financial assistance toward patients’ health insurance premiums.

The shareholder class action complaint alleges that DaVita and certain of its executive officers made a series of materially false and misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects to investors during the Class Period, including the following: (1) that the Company and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) that the Company was using AKF as a vehicle to facilitate these improper practices; (3) that, as a result, DaVita’s revenues and profits were illegally obtained; and (4) that DaVita lacked effective internal controls over financial reporting. The complaint further alleges that, as a result of the foregoing, the defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On August 18, 2016, The Centers for Medicare & Medicaid Services issued a public request for information regarding the alleged steering of Medicare and Medicaid beneficiaries into other plans in order to earn higher reimbursement rates. Following this news, shares of the Company’s stock declined $3.17 per share, or 4.7%, to close on August 19, 2016 at $64.48 per share.

Then, on October 23, 2016, the St. Louis Post published an article entitled, “DaVita encouraged some low-income patients to enroll in commercial plans,” which directly accused DaVita of steering clients to private insurers and utilizing its own money to pay for health insurance premiums through the AKF. Following this news, shares of the Company’s stock declined an additional $2.86 per share, or 4.7%, to close on October 24, 2016 at $58.10 per share.

Subsequently, on January 6, 2017, The Wall Street Journal reported that investigators from the U.S. Department of Justice “are probing a controversial arrangement under which kidney-care companies support charitable efforts to help patients pay health-insurance premiums, according to disclosures from major dialysis providers.” Additionally, the article reported that the “Boston U.S. attorney’s office has subpoenaed DaVita Inc. …seeking ‘the production of information related to charitable premium assistance.'”

DaVita shareholders may, no later than April 3, 2017, petition the Court to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. For additional information, or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/davita-inc#join.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP

Darren J. Check, Esq.

D. Seamus Kaskela, Esq.

Adrienne O. Bell, Esq.

280 King of Prussia Road

Radnor, PA 19087

(888) 299-7706

(610) 667-7706

info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 454557

IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 27, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (NASDAQ: RGLS). Investors, who purchased or otherwise acquired Regulus shares between January 21, 2016 and June 27, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 3, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

Regulus revealed that it was contacted by the U.S. Food and Drug Administration (“FDA”), stating that its new drug against the chronic hepatitis C virus infection will be placed on clinical hold due to another incidence of jaundice.

On January 27, 2017, Regulus disclosed that the FDA would not remove the clinical hold on RG-101 until the agency confirms the last safety and efficacy information from continued clinical and pre-clinical studies.

When this information was revealed to the investing public, shares of Regulus fell sharply, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 456051

IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against USANA Health Sciences, Inc., and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / February 27, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against USANA Health Sciences, Inc. (“USANA” or the “Company”) (NYSE: USNA) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired shares between March 14, 2014 and February 7, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 14, 2017 lead plaintiff motion deadline.

If you purchased shares of USANA during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

USANA develops, manufactures, and sells nutritional and personal care products primarily to reduce the risk of chronic degenerative disease.

On February 7, 2017, USANA revealed that it will be starting an internal investigation of its Chinese subsidiary, BabyCare Ltd. (“BabyCare”).

In particular, the Company’s investigation concerns “compliance with the Foreign Corrupt Practices Act,” as well as “BabyCare’s expense reimbursement policies.”

When this information was revealed to the investing public, the value of USANA declined, causing investors harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 456059

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 27, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (NASDAQ: SGEN) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Seattle Genetics shares between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”), are encouraged to contact the firm prior to the March 17, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, the Company announced that the U.S. Food and Drug Administration had enforced a clinical hold or partial clinical hold on initial stage trials of the Company’s experimental cancer drug, vadastuximab talirine, to assess any possible risk of hepatotoxicity. The Company mentioned that six acute myeloid leukemia patients had been identified with liver toxicity and that four had died.

When this news was released to the public, the value of Seattle Genetics dropped, causing investors serious harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

SOURCE: Lundin Law PC

ReleaseID: 456050

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Innocoll Holdings, plc (INNL) and Lead Plaintiff Deadline: March 27, 2017

NEW YORK, NY / ACCESSWIRE / February 27, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Innocoll Holdings, plc (“Innocoll” or the “Company”) (NASDAQ: INNL) and certain of its officers, on behalf of shareholders who purchased Innocoll securities between November 3, 2016 through December 29, 2016, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/innl.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) consequently, Defendants’ statements regarding Innocoll’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On December 29, 2016, Innocoll revealed that it had received a Refusal to File letter from the U.S. Food & Drug Administration (“FDA”) regarding its New Drug Application for XARACOLL, a postsurgical pain treatment and the Company’s lead product candidate. Innocoll said that the FDA stated that XARACOLL should have been categorized as a drug/device combination which would necessitate additional information. Following this news, Innocoll stock has dropped up to 66%, damaging investors.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/innl, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Innocoll, you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 453533

DEADLINE ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novo Nordisk A/S (NVO) and Lead Plaintiff Deadline: March 13, 2017

NEW YORK, NY / ACCESSWIRE / February 27, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Novo American Depositary Receipts (“ADR”) between April 30, 2015 and October 27, 2016, both dates inclusive (the “Class Period”). Investors with losses in excess of $1 million are advised to join this case by visiting the firm’s site: http://www.bgandg.com/nvo.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Novo reported materially false and misleading Company earnings and predications, in that they were inflated through the collusive price fixing of Novo’s insulin drugs. The Complaint also alleges that Novo misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/nvo, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. Investors with losses in excess of $1 million in Novo, you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 452766